Status:
UNKNOWN
Risk of HCC in Cirrhotic Patients Post DAAs Ttt
Lead Sponsor:
Assiut University
Conditions:
HCC
Eligibility:
All Genders
18-70 years
Brief Summary
Direct acting antivirals (DAAs) are a novel and completely oral hepatitis C therapy . DAAs are used in most patients being treated for hepatitis C, including those with decompensated cirrhosis. This t...
Detailed Description
HCV is a worldwide infection, it is estimated that about at about 3.0% (170-200 million people) of the world's population are infected. HCV is associated with an increased disease burden due to liver ...
Eligibility Criteria
Inclusion
- Patients with HCV-related liver cirrhosis (eligible for treatment) who developed (HCC) after DAAs therapy within one year follow up.
- Age and sex matched group of patients with HCV- related liver cirrhosis who didn't develop HCC after DAAs therapy within one year follow up(as control group)
- Patients with chronic HCV related liver cirrhosis complicated by hepatocellular carcinoma not eligible for treatment.(discovered during enrollment in HCV treatment program)
Exclusion
- Patients who refuse to participate in the study.
- Patients with hepatitis B virus, any other causes of cirrhosis.(Alcohol consumpation, Biliary, Cardiac…..etc)
- Patients with cancers other than HCC or metastatic liver cancer.
- Patients who developed HCC on transplanted liver.
- Patients who previously treated for HCC.
- Patients who receive any immunosuppression drugs.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03414554
Start Date
February 1 2018
End Date
February 28 2019
Last Update
January 30 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.